Subsidy Information and Financing Scheme MAFFedratinib Capsule 100 mg For the treatment of splenomegaly and/or disease related symptoms in patients with intermediate-2 o... See all × MAFFedratinib Capsule 100 mg For the treatment of splenomegaly and/or disease related symptoms in patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib. MSHLFedratinib Capsule 100 mg For the treatment of splenomegaly and/or disease related symptoms in patients with intermediate-2 o... See all × MSHLFedratinib Capsule 100 mg For the treatment of splenomegaly and/or disease related symptoms in patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.
Post Marketing Information DHCPL 17/11/2022 Risk of major adverse cardiovascular events, malignancy, thrombosis and death associated with use of Janus Kinase (JAK) inhibitors
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 100 mg National Cancer Centre Tan Tock Seng Hospital